Perjeta Breast Cancer Drug Shows 'Unprecedented' Benefits For Extended Survival

September 29, 2014 9:21 AM

6 0

Perjeta Breast Cancer Drug Shows 'Unprecedented' Benefits For Extended Survival

A new breast cancer treatment by the Swiss drug maker Roche has increased median survival time for patients by an average of nearly sixteen months, according to health officials. The drug, known as Perjeta, was found to provide unprecedented success to fight the disease based on a recent clinical study.

The recent results are the longest to date for a medication used in the initial treatment for a metastatic breast cancer drug of any kind, according to the Diabetes Insider.

Read more

To category page

Loading...